Suowen Xu

Tirzepatide attenuates atherosclerosis through weight loss-independent anti-inflammatory mechanisms

This paper shows tirzepatide reduces atherosclerosis independently of weight loss by directly targeting vascular inflammation through the cAMP/PKA/eNOS pathway.

Desert hedgehog enhances endothelial resilience and prevents atherosclerosis by mitigating PAI-1 signaling

This study identifies desert hedgehog (DHH) as a resilience factor that prevents atherosclerosis by inhibiting PAI-1 signaling and endothelial mesenchymal transition.

TWIST1 drives endothelial-to-mesenchymal-transition to stabilize atherosclerotic plaques

Endothelial Twist1 drives partial and advanced endothelial-to-mesenchymal transition via PELP1 and AEBP1-COL4A1 signaling, increasing collagen and ACTA2+ cells to stabilize atherosclerotic plaques in male mice and human carotid arteries.

Neratinib, a clinical drug against breast cancer, protects against atherosclerosis via ASK1 inhibition

Neratinib reduces atherosclerosis by inhibiting ASK1-mediated endothelial inflammation, showing potential as a repurposed drug for vascular disease.

Re-evaluating the Impact of Biological Sex on Atherosclerosis in Apoe-/- and Ldlr-/- mice

This study evaluates the impact of biological sex on atherosclerosis in Apoe-/- and Ldlr-/- mice, finding sex-dependent differences in plaque burden and metabolic parameters.

Colchicine Inhibits Smooth Muscle Cell Phenotypic Switch and Aortic Dissection in Mice

This study shows colchicine prevents aortic dissection in mice by inhibiting vascular inflammation and smooth muscle cell phenotypic transformation.

Endothelial MICU1 protects against vascular inflammation and atherosclerosis by inhibiting mitochondrial calcium uptake

This study shows that endothelial MICU1 prevents vascular inflammation and atherosclerosis by maintaining mitochondrial calcium homeostasis and reducing mitochondrial reactive oxygen species.

The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

This study shows halofuginone, an FDA-approved drug, reduces obesity in mice by increasing FGF21 and GDF15 levels, improving metabolic health.